Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease

Experimental Neurology

Volumn 144, Issue 1, 1997, Pages 147-156

  Bankiewicz, Krzysztof S ^a   Leff, Stuart E ^a   Nagy, Dea ^a   Jungles, Steve ^a   Rokovich, Joseph ^a   Spratt, Kaye ^a   Cohen, Lawrence ^a   Libonati, Michele ^a   Snyder, Richard O ^a   Mandel, Ronald J ^a  

^a CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 19244383907     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1996.6401     Document Type: Article

References (62)

1. 1. Acsadi, G., S. S. Jiao, A. Jani, D. Duke, P. Williams, W. Chong, and J. A. Wolff. 1991. Direct gene transfer and expression into rat heart in vivo. New Biol. 3: 71-81.
2. 2. Agid, Y., F. Javoy-Agid, and M. Ruberg. 1987. Biochemistry of neurotransmitters in Parkinson's disease. Pages 166-230 in C. D. Marsden and S. Fahn, Eds., Movement Disorders 2. Butterworths, London.
3. 3. Bankiewicz, K. S. 1991. MPTP-induced Parkinsonism in nonhuman primates. Methods Neurosci. 7: 168-182.
4. 4. Bankiewicz, K. S., E. H. Oldfield, C. C. Chiueh, J. L. Doppman, D. M. Jacobowitz, and I. J. Kopin. 1986. Hemisparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39: 7-16.
5. 5. Bankiewicz, K. S., R. Snyder, S. Z. Zhou, J. Morton, J. Conway, and D. Nagy. 1996. Adeno-associated viral vector-mediated gene delivery in a non-human primates. Soc. Neurosci. Abst. 22: 768. [Abstract]
6. 6. Barbeau, A. 1961. Biochemistry of Parkinson's disease. Int. Congr. Series 38: 152-153.
7. 7. Bensics, C., S. R. Wachtel, S. Milstien, K. Hatakeyama, J. B. Becker, and U. J. Kang. 1996. Double transduction with GTP cyclohydrolase 1 and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J. Neurosci. 16: 1556-1561.
8. 8. Bernheimer, H., W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. J. Neurol. Sci. 20: 415-455.
9. 9. Birkmayer, W., and O. Hornykiewicz. 1961. Effekt bei der parkinson akinesia. Klin. Wochenschr. 73: 787-788.
10. 10. Blasberg, R., C. Patlak, and J. Fenstermacher. 1975. In chemotherapy: Brain tissue profiles after ventriculociste fusion. J. Pharmacol. Exp. Ther. 2: 73-83.
11. 11. Bringas, J. R., E. M. Kutzscher, B. M. Yang, R. S. Hundal, D. Nagy, W. W. McLaughlin, S. Leff, M. E. Emborg, S. Jungels, and K. S. Bankiewicz. 1996. Implantation parameters for reliable delivery of cells into the striatum of monkeys using an automated delivery system. Soc. Neurosci. Abst. 22: 319. [Abstract]
12. 12. Burns, R. S., C. C. Chiueh, S. P. Markey, M. H. Ebert, D. M. Jacobowitz, and I. J. Kopin. 1983. Aprimate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 890: 4546-4550.
13. 13. Caillaud, C., S. Akli, E. Vigne, A. Koulakoff, M. Perricaudet, L. Poenaru, A. Kahn, and Y. Berwaldnetter. 1993. Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells. Eur. J. Neurosci. 5: 1287-1291.
14. 14. Chase, T. N., J. Juncos, C. Serrati, G. Fabbrini, and G. Bruno. 1987. Fluctuation in response to chronic levodopa therapy: Pathogenetic and therapeutic considerations. Adv. Neurol. 45: 477-480.
15. 15. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543.
16. 16. Elsworth, J. D., A. Y. Deutch, D. E. Redmond, Jr., J. R. Sladek, and R. H. Roth. 1987. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Res. 415: 293-299.
17. 17. Emerich, D. F. W., S. R. Winn, J. Harper, J. P. Hammang, E. E. Baetge, and J. H. Kordower. 1994. Implants of polymerencapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol. 349: 148-164.
18. 18. Federoff, H. J., M. D. Geschwind, A. I. Geller, and J. A. Kessler. 1992. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc. Natl. Acad. Sci. USA 89: 1636-1640.
19. 19. Ferguson, I. A., J. B. Schweitzer, P. F. Bartlett, and E. M. Johnson, Jr. 1991. Receptor-mediated retrograde transport in CNS neurons after intraventricular administration of NGF and growth factors. J. Comp. Neurol. 313: 680-692.
20. 20. Fisher, L. J., H. A. Jinnah, L. C. Kale, G. A. Higgins, and F. H. Gage. 1991. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6: 371-380.
21. 21. Freese, A., B. A. Sabel, W. M. Saltzman, M. J. During, and R. Langer. 1989. Controlled release of dopamine from a polymeric brain implant: in vitro characterization. Exp. Neurol. 103: 234-238.
22. 22. Geller, A. I., and X. O. Breakefield. 1988. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241: 1667-1669.
23. 23. Geller, A. I., and A. Freese. 1990. Transfection of cultured central nervous system neurons with defective HSV-1 vector which expresses β-galactosidase. Proc. Natl. Acad. Sci. USA 87: 1149-1153.
24. 24. Glorioso, J. C., W. F. Goins, C. A. Meaney, D. J. Fink, and N. A. De Luca. 1994. Gene transfer to brain using herpes simplex virus vectors. Ann. Neurol. 35 (Suppl.): S28-S34.
25. 25. Gregoriadis, G. 1976. The carrier potential of liposomes in biology and medicine. N. Engl. J. Med. 295: 704-710.
26. 26. Harder, S., H. Bass, and S. Rietbrock. 1995. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin. Pharmacokinet. 29: 243-256.
27. 27. Hargraves, R., and W. J. Freed. 1986. Chronic intrastriatal dopamine infusions in rats with unilateral lesions of the substantia nigra. Life Sci. 40: 959-966.
28. 28. Henderson, B. T., C. G. Clough, R. C. Hughes, E. R. Hitchcock, and B. G. Kenny. 1991. Implantation of human ventral mesencephalon to the right caudate nucleus in advance parkinsons disease. Arch. Neurol. 48: 822-827.
29. 29. Horellou, P., P. Brundin, P. Kalen, J. Mallet, and A. Bjorklund. 1990. In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 5: 393-402.
30. 30. Horellou, P., L. Marlier, A. Privat, and J. Mallet. 1990. Behavioral effect of engineered cells that synthesize L-dopa or dopamine after grafting into the rat neostriatum. Eur. J. Neurosci. 2: 116-119.
31. 31. Javoy-Agid, F., E. C. Hirsch, S. Dumas, C. Duyckaerts, J. Mallet, and Y. Agid. 1990. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantial nigra in parkinsons disease an in situ hybridization study. Neuroscience 38: 245-253.
32. 32. Javoy-Agid, F., M. Ruberg, L. Pique, X. Bertagna, H. Taquet, J. M. Studler, F. Cesselin, J. Epelbaum, and Y. Agid. 1984. Biochemistry of the hypothalamus in Parkinson's disease. Neurology 34: 672-675.
33. 33. Jiao, S., P. Williams, R. K. Berg, B. A. Hodgeman, L. Liu, G. Repetto, and J. A. Wolff. 1992. Direct gene transfer into nonhuman primate myofibers in vivo. Hum. Gene Ther. 3: 21-33.
34. 34. Rang, U. J., L. J. Risher, T. H. Joh, K. L. O'Malley, and F. H. Gage. 1993. Regulation of dopamine production by genetically modified primary fibroblasts. J. Neurosci. 13: 5203-5211.
35. 35. Kaplitt, M. G., X. Xiao, R. J. Samulski, J. Li, M. J. Kaplitt, K. Ojamm, I. Klein, R. K. Strumpf, H. Makimura, J. L. Breslow, and E. B. Diethrich. 1996. Long term gene transfer into procine myocardium following selective percutaneous coronary artery infusion of an adeno-associated virus vector. Ann. Thorac. Surg., 62: 1669-1676.
36. 36. Kebabian, J. W., and D. B. Calne. 1979. Multiple receptors for dopamine. Nature 277: 93-96.
37. 37. Kordower, J. H., T. B. Rreeman, B. J. Snow, F. J. Vingerhoets, E. J. Mufson, P. R. Sanberg, R. A. Hauser, D. A. Smith, G. M. Nauert, D. P. Perl et al. 1995. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease [see comments]. N. Engl. J. Med. 332: 1118-1124.
38. 38. Krewson, C. E., M. L. Klarman, and W. M. Saltzman. 1995. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 680: 196-206.
39. 39. Langston, J. W., P. Ballard, J. W. Tetrud, and I. Irwin. 1983. Chronic parkinsonism in humans due to a product of meperidineanalog synthesis. Science 219: 979-980.
40. 40. Le Gal La Salle, G., J. J. Robert, S. Berrard, V. Ridoux, L. D. Stratford-Perricaudet, M. Perricaudet, and J. Mallet. 1993. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259: 988-990.
41. 41. Lee, T., P. Seeman, A. Rajput, I. J. Farley, and O. Hornykiewicz. 1978. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273: 59-61.
42. 42. Leff, S. E., K. G. Clevenger, D. G. Wu, F. F. Jaret, and R. J. Mandel. 1997. Expression of GTP-cylcohydrolase 1 (GTP-CH1) and tyrosine hydroxylase (TH) but not TH alone in the 9L gliosarcome cell line enables in vivo measurement of L-dopa via microdialysis. Exp. Neurol., in press.
43. 43. Levine, R. A., L. P. Miller, and W. Lovenberg. 1981. Tetrahydrobiopterin in striatum: localization in dopamine nerve terminals and role in catecholamine synthesis. Science 214: 919-921.
44. 44. Lieberman, D. M., P. Morrison, K. S. Bankiewicz, and E. H. Oldfield. 1995. Convection-enhanced distribution of large molecules in gray matter during interstitial infusion. J. Neurosurg. 82: 1021-1029.
45. 45. Lindvall, O., G. Sawle, H. Widner, J. C. Rothwell, A. Bjorklund, D. Brooks, P. Brundin, R. Frackowiak, C. D. Marsden, P. Odin, and S. Rehncrona. 1994. Evidence for Long-Term survival and function of dopaminergic grafts in progressive parkinsons disease. Ann. Neurol 35: 172-180.
46. 46. McCown, T. J., X. Xiao, J. Li, G. R. Breese, and R. J. Samulski. 1996. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713: 99-107.
47. 47. Melamed, E., and F. Hefti. 1984. Mechanism of action of short-and long-term L-DOPA treatment in Parkinsonism: Role of the surviving nigrostriatal dopaminergic neurons. Pages 149-157 in R. G. Hassler and J. F. Christ, Eds., Advances in Neurology, Vol. 40. Raven Press, New York.
48. 48. Muzyczka, N. 1992. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158: 97-129.
49. 49. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. Gage, I. Verma, and D. Tronto. 1996. In vivo gene delivery and stable transduction of nondividing cells by lentiviral vector. Science 727: 263-267.
50. 50. Obeso, J. A., F. Grandas, M. T. Herrero, and R. Horowski. 1994. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in parkinson's disease. Eur. J. Neurosci. 6: 889-897.
51. 51. Pardridge, W. M. 1991. Peptide Drug Delivery to the Brain. Raven Press, New York.
52. 52. Saltzman, W. M., M. L. Radomsky, K. J. Whaley, and R. A. Cone. 1991. Drugs released from polymers: Diffusion and elimination in brain tissue. Chem. Eng. Sci. 46: 2429-2444.
53. 53. Samulski, R. J. 1993. Adeno-associated virus: Integration at a specific chromosomal locus. Curr. Opin. Genet. Dev. 3: 74-80.
54. 54. Samulski, R. J., L. S. Chang, and T. Shenk. 1989. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63: 3822-3828.
55. 55. Scatton, B., F. Javoy-Agid, L. Rouquier, B. Dubois, and Y. Agid. 1983. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275: 321-328.
56. 56. Snyder, R. O., X. Xiao, and R. J. Samulski. 1996. Production of recombinant adeno-associated viral vectors. Pages 1-24 in H. Dracopoli, J. Haines, B. Krof, C. Moir, C. Morton, C. Seidman, J. Seidman, and D. Smith, Eds., Current Protocols in Human Genetics. Wiley, New York.
57. 57. Uchida, K., K. Takamatsu, N. Kaneda, S. Toya, Y. Tsukada, Y. Kurosawa, K. Fujita, T. Nagatsu, and S. Kohsaka. 1989. Synthesis of L-3,4-dihydroxyphenylalanine by tyrosine hydroxylase cDNA-transfected C6 cells: application for intracerebral grafting. J. Neurochem. 53: 728-732.
58. 58. Wang, J., K. S. Bankiewicz, R. J. Plunkett, and E. H. Oldfield. 1994. Intrastriatal implantation of interleukin-1-reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain. J. Neurosurg. 80: 484-490.
59. 59. Weitzman, M. D., S. R. Kyostio, R. M. Kotin, and R. A. Owens. 1994. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc. Natl. Acad. Sci. USA 91: 5808-5812.
60. 60. Wolff, J. A., L. J. Fisher, L. Xu, H. A. Jinnah, P. J. Langlais, P. M. luvone, K. L. O'Malley, M. B. Rosenberg, S. Shimohama, T. Friedmann, and et al. 1989. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA 86: 9011-9014.
61. 61. Wolff, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, and P. L. Felgner. 1990. Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
62. 62. Zigmond, M. J., E. D. Abercrombie, T. W. Berger, A. A. Grace, and E. M. Stricker. 1990. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13: 290-296.